miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance

Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R.
PLoS One. 2014 Jun 3;9(6):e98597. doi: 10.1371/journal.pone.0098597. eCollection 2014.